Company Description
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.
The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.
Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis.
Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target α-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43.
The company was incorporated in 2012 and is based in Dublin, Ireland.
| Country | Ireland |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 173 |
| CEO | Gene Kinney |
Contact Details
Address: 77 Sir John Rogerson’s Quay, Block C Dublin, D02 VK60 Ireland | |
| Phone | 353 1 236 2500 |
| Website | prothena.com |
Stock Details
| Ticker Symbol | PRTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001559053 |
| CUSIP Number | G72800108 |
| ISIN Number | IE00B91XRN20 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gene G. Kinney Ph.D. | President, Chief Executive Officer and Director |
| Tran B. Nguyen M.B.A. | Chief Financial Officer and Chief Strategy Officer |
| Brandon S. Smith | Chief Operating Officer |
| Carol D. Karp | Chief Regulatory Officer |
| Karin L. Walker CPA | Chief Accounting Officer and Controller |
| Dr. Wagner M. Zago Ph.D. | Chief Scientific Officer |
| Mark C. Johnson C.F.A. | Vice President of Investor Relations |
| Michael J. Malecek | Chief Legal Officer |
| David A. Ford | Chief People Officer |
| Dr. Chad J. Swanson Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 27, 2024 | 8-K | Current Report |
| Aug 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |